Quarterly report [Sections 13 or 15(d)]

Basis of Presentation and Summary of Significant Accounting Policies - Investments (Details)

v3.25.1
Basis of Presentation and Summary of Significant Accounting Policies - Investments (Details)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Mar. 31, 2023
USD ($)
Aug. 31, 2024
shares
Jul. 31, 2024
USD ($)
Dec. 31, 2021
USD ($)
Mar. 31, 2025
USD ($)
Mar. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Mar. 31, 2025
USD ($)
segment
Mar. 31, 2024
USD ($)
Jun. 30, 2024
USD ($)
Jun. 30, 2023
USD ($)
Dec. 31, 2024
USD ($)
Number of Operating Segments | segment               2        
Payments in Investment               $ 15,000 $ 0      
Gain (loss) on equity method investment         $ (589) $ (1,747)   (169) (5,950)      
Positions eliminated during the period as a percentage             4.00%          
Impairment charges related to the disposal group               (3,655) 6,038      
Number of expired vested stock options (in shares) | shares   791,204                    
Number of expired vested stock options covered in first settlement payment (in shares) | shares   791,204                    
Litigation charges         38,900 0   40,600 0      
Accrued litigation         0     0   $ 0    
Former CEO                        
Payment for settlement of litigation         37,200              
Number of expired vested stock options covered in first settlement payment (in shares) | shares   779,084                    
Former employees excluding former CEO                        
Payment for settlement of litigation         500              
Number of expired vested stock options covered in first settlement payment (in shares) | shares   12,120                    
Protein Sciences                        
Goodwill attributable to disposal group held for sale             $ 1,400          
Recovery         3,700     3,700        
Inventory, sold as part of disposal group                       $ 8,000
Promissory note related to sale of inventory of disposal group         6,000     6,000        
Pre-tax restructuring charges                   200 $ 1,700  
Protein Sciences | Current Assets, Held For Sale | Fiscal Year 2024 Restructuring Actions                        
Property, plant and equipment attributable to disposal group held for sale         $ 4,700     $ 4,700        
Wilson Wolf Corporation                        
Payments in Investment $ 232,000     $ 25,000                
Investment percentage 19.90%                      
Forward Contract, Milestone, Multiple for Total Expected Payments         4.4     4.4        
Gain (loss) on equity method investment         $ (600) $ (1,700)   $ (200) $ (6,000)      
Investment amount         239,500     239,500   242,300    
Wilson Wolf Corporation | Second Part of Forward Contract                        
Forward Contract, Milestone, Annual Revenue Required         226,000     226,000        
Forward Contract, Milestone, Annual EBITDA         136,000     136,000        
Forward Contract, Additional Investment         1,000,000     1,000,000        
Spear Bio                        
Payments in Investment     $ 15,000                  
Spear Bio | Other assets                        
Long-term investments         $ 15,000     $ 15,000        
Selling, General and Administrative Expenses | Protein Sciences | Fiscal Year 2024 Restructuring Actions                        
Asset Impairment Charges                   $ 22,000